Checkpoint Inhibitors Show Promise against Aggressive Pediatric Brain Cancer

Supratentorial ependymoma in a 10-year-old girl on a noncontrast CT. [E.L. Yuh , A.J. Barkovich, N. Gupta, Childs Nerv Syst (2009)]

Immunotherapy continues to prove its mettle in the fight against various forms adult cancers ranging from melanoma to lung cancer, to kidney cancer, and more. For instance, drugs that target immune checkpoint pathways, such as programmed cell death protein 1 (PD-1), help remove the genetic blindfold that cancer uses to hide from the immune system. Now, PD-1 inhibitors are entering clinical trials to treat childhood cancers, and investigators at the University of Colorado Cancer Center have new data that they believe groundwork for the use of PD-1 inhibitors with an aggressive form of brain cancer called supratentorial pediatric ependymoma. Findings from the new study were published recently in Pediatric Blood Cancers, in an article entitled “Specific Expression of PD-L1 in RELA-Fusion Supratentorial Ependymoma: Implications for PD-1-Targeted Therapy.”

The tumor, which occurs in the upper part of the brain, namely the cerebral hemisphere, has two common genetic causes. The current study focuses on those tumors driven by changes to the gene RELA. When this gene improperly fuses with a partner gene, the resulting protein amplifies the action of a cancer-causing cascade of signals through a network called NF-κB, which is implicated in many cancer types.

“This is a tumor with poor prognosis,” noted co-senior study investigator Andrea Griesinger, senior professional research assistant in the laboratory of co-senior study investigator Nick Foreman, M.D., a CU Cancer Center investigator and Seebaum/Tschetter Chair of Pediatric Neuro-Oncology at Children's Hospital Colorado. “Overall, pediatric cancers have a nearly 90% survival rate. But only 60% of patients with the most common form of supratentorial ependymoma will be alive five years after diagnosis.”

“RELA-fusion hasn't been found in other cancer types,” added lead study investigator Davis Witt, professional research assistant in Dr. Foreman’s laboratory. “But NF-κB amplification by other means is fairly common in cancer. RELA-fusion is another way to amplify NF-κB, which causes this cancer.”

Yet, just as these supratentorial RELA-fusion pediatric ependymomas have genetic features that drive their growth, the research team showed that these tumors have a feature that may be a kind of Achille's heel that allows them to be killed. Specifically, the study shows that unlike other variations of pediatric ependymoma, the tumors driven by RELA-fusion coat themselves in the protein PD-L1, or programmed death-ligand 1. This PD-L1 on the surface of cancer cells interacts with the protein PD-1 on immune system T cells to inactivate T cells against cancer cells. It's as if PD-L1 is cancer's “white flag” that is seen by PD-1 “eyes” on immune system T cells. PD-1 inhibitors block the interaction between PD-L1 and PD-1, and thus nix cancer cells' ability to turn off the immune system.

“A major hurdle in ependymoma research has been a lack of cell lines and animal models,” explained Ms. Griesinger. “Over the last five years, we've been actively developing these cell lines that allow us to examine the biologic features of this disease. Just last week we were finally able to use these cells lines to develop an animal model of the disease, which will allow us to test likely treatments, in this case possibly anti-PD-1 drugs.”

In fact, a clinical trial of the anti-PD-1 drug nivolumab recently opened to treat pediatric brain tumors. In early-phase clinical trials, investigators expect that some patients will benefit while others will not. The current study may hint at which pediatric brain cancer patients are most likely to see benefit from nivolumab or other anti-PD-L1 drugs, namely patients with these supratentorial RELA-fusion pediatric ependymomas that use PD-L1 so extensively.

“It's almost like we're backfilling the science behind this trial and providing information to use when designing future trials,” Mr. Witt remarked. “If the trial doesn't work, we could go back and say 'hey, we just picked the wrong tumor,' and perhaps focus on this subtype of pediatric brain cancer that, according to the science, should be especially susceptible to PD-1 inhibitors.”

Now that early cell studies have proved promising, Witt, Griesinger, and other members of the Foreman lab plan to continue exploring the use of PD-1 inhibitors against supratentorial RELA-fusion pediatric ependymomas. This will include drug testing against cell lines and the development of “humanized” mouse models in which animals with this type of tumor are engineered to hold a version of the human immune system, allowing investigators to evaluate human-like immune responses against cancer.

“This RELA-fusion subgroup is uniquely expressing high levels of PD-1. At this point, we're all very hopeful this means these tumors will be susceptible to anti-PD-1 drugs,” Mr. Witt concluded.